A new mucosal adjuvant for augmenting influenza vaccines in elderly
一种用于增强老年人流感疫苗接种效果的新型粘膜佐剂
基本信息
- 批准号:10304406
- 负责人:
- 金额:$ 48.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-24 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdjuvantAdjuvanticityAgeAgingAgonistAirAlveolar MacrophagesAntigen TargetingAntigen-Presenting CellsAttenuatedBiological Response ModifiersBiomimeticsCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCOVID-19COVID-19 pandemicCause of DeathCell AgingCellsCellular ImmunityCessation of lifeClinicalCyclic GMPCytosolDefectDendritic CellsDiseaseDistantEffectivenessElderlyEncapsulatedEndocytosisEngineeringEpithelial AttachmentEpithelial CellsExcisionFaceFerretsGene ActivationGenesH1N1 vaccineHealthHealthcare SystemsHospitalizationHumoral ImmunitiesITGAM geneImmuneImmune responseImmune systemImmunityImmunizationImmunization ProgramsInfectionInflammagingInflammationInfluenzaInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza A Virus, H7N9 SubtypeInfluenza vaccinationInhalationInterferonsInvadedLearningLiposomesLongevityLungMediatingMedicalMembraneMemoryMiddle East Respiratory SyndromeModelingMonitorMucous MembraneMusNamesNatureOrganPhospholipase A2PlayPopulationPredispositionProductionPublic HealthPulmonary Surfactant-Associated Protein APulmonary SurfactantsRespiratory SystemRoleScienceSevere Acute Respiratory SyndromeSingle Nucleotide PolymorphismStructure of parenchyma of lungT cell responseT memory cellT-LymphocyteTissuesTsunamiVaccinationVaccinesViral Respiratory Tract InfectionViral VaccinesVirusVirus Diseasesagedaging populationalveolar epitheliumbasecostfluimmunopathologyimprovedinfluenza virus vaccineinterestmemory CD4 T lymphocytemortalitynovelparticlepreventrecruitrespiratoryresponseuniversal influenza vaccinevaccination strategyyoung adult
项目摘要
Abstract
This proposal is to investigate a newly developed mucosal adjuvant for its effectiveness in bolstering
influenza (flu) vaccines in the elderly. Current flu vaccines are inefficacious in the elderly owing to the
aged immune system and their poor stimulation of cell-mediated immunity (CMI). A powerful adjuvant
capable of stimulating both humoral and cell immune responses in the elderly should greatly augment
existing flu vaccines, better safeguarding this aging and growing population. We recently engineered a
powerful mucosal adjuvant by encapsulating a natural STING agonist with pulmonary surfactant (PS)-
biomimetic liposomes, named PS-GAMP, based on recent findings that activation of STING, the
stimulator of IFN genes, can vigorously stimulate CMI and humoral immunity. PS-GAMP alongside
inactivated H1N1 vaccine induced a wide spectrum of cross-protection against distant H1N1 and
heterosubtypic H3N2, rgH5N1, and H7N9 viruses as early as 2 days after a single immunization. The
cross-protection lasted for at least 6 months, concurrent with durable lung tissue resident memory (TRM)
CD8+ T cells in young adult mice. We will extend the study to aged mice in this proposal and determine
whether strong CD8+ T-cells (and perhaps CD4+ T cells as well) can be quickly induced by PS-GAMP/flu
vaccine in aged mice. We will monitor a longevity of the heterosubtypic immunity, humoral immune
responses, and lung TRM CD8+ and CD4+ memory T cells as mice age. Because the vaccination does
not involve any replicating vaccine, pre-exiting immunity should have little effect on the efficacy of PS-
GAMP/flu vaccination, which will be investigated to demonstrate significant advantages of the vaccine
over live-attenuated intranasal flu vaccine that is ineffective in the elderly. Secondly, distinguished from
most prominent adjuvants primarily targeting antigen-presenting cells (APCs) or professional immune
cells, PS-GAMP activates both alveolar epithelial cells (AEC) and APCs. It would be interested to learn
whether PS-GAMP-mediated AEC activation can offset the defects of aged APCs, eliciting strong
heterosubtypic immunity in aged mice. The pivotal role for AEC will be also substantiated in ferret model.
Aim 3 will investigate whether PS-GAMP/flu vaccination can be further improved in aged mice by
suppressing inflammaging and/or removing senescence cells. Moreover, a novel, much more potent, and
pan-STING agonist will be explored to enhance PS-GAMP’s adjuvanticity and strengthen its clinical
potential. The study, if successful, would have significant impact on the overall health and quality of the
aged population not only for influenza but also for other respiratory viral infections like Covid-19.
摘要
这项建议是调查一种新开发的粘膜佐剂,其有效性,在支持
老年人接种流感疫苗。目前的流感疫苗对老年人无效,
老化的免疫系统和它们对细胞介导的免疫(CMI)的不良刺激。强效佐剂
能够刺激老年人的体液和细胞免疫反应的药物,
现有的流感疫苗,更好地保护老龄化和不断增长的人口。我们最近设计了一个
通过将天然STING激动剂与肺表面活性剂(PS)包封,
仿生脂质体,命名为PS-GAMP,基于最近的发现,STING的激活,
IFN基因的刺激因子,能强烈刺激CMI和体液免疫。PS-GAMP与
灭活H1N1疫苗诱导了针对远距离H1N1的广谱交叉保护,
H3 N2、rgH 5 N1和H7N9病毒的感染。的
交叉保护持续至少6个月,同时具有持久的肺组织驻留记忆(TRM)
年轻成年小鼠中的CD 8 + T细胞。我们将在本提案中将研究扩展到老年小鼠,并确定
PS-GAMP/流感病毒是否能快速诱导强的CD 8 + T细胞(也许还有CD 4 + T细胞)
老年小鼠的疫苗。我们将监测一个长寿的异型免疫,体液免疫,
随着小鼠年龄的增长,肺TRM CD 8+和CD 4+记忆T细胞的变化。因为接种疫苗
不涉及任何复制疫苗,预先存在的免疫力应该对PS的效力几乎没有影响,
GAMP/流感疫苗接种,将对其进行研究,以证明疫苗的显著优势
对老年人无效的鼻内减毒活流感疫苗。其次,区别于
主要靶向抗原呈递细胞(APC)或专职免疫细胞的最突出的佐剂
细胞,PS-GAMP激活肺泡上皮细胞(AEC)和APC。我很想知道
PS-GAMP介导的AEC激活是否可以抵消老化APC的缺陷,引起强烈的免疫反应,
老年小鼠的异亚型免疫。AEC的关键作用也将在雪貂模型中得到证实。
目的3将研究PS-GAMP/流感疫苗接种是否可以通过以下方法在老年小鼠中进一步改善:
抑制炎症和/或去除衰老细胞。此外,一部小说,更有力,
我们将探索一种泛STING激动剂,以增强PS-GAMP的佐剂性,加强其临床应用
潜力这项研究如果成功,将对儿童的整体健康和质量产生重大影响。
老年人不仅是流感,也是其他呼吸道病毒感染,如COVID-19。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mei X Wu其他文献
Mei X Wu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mei X Wu', 18)}}的其他基金
A new mucosal adjuvant for augmenting influenza vaccines in elderly
一种用于增强老年人流感疫苗接种效果的新型粘膜佐剂
- 批准号:
10409833 - 财政年份:2021
- 资助金额:
$ 48.27万 - 项目类别:
Delivery of Powdered Vaccines for Improving Newborn Vaccination
提供粉状疫苗以改善新生儿疫苗接种
- 批准号:
10092941 - 财政年份:2020
- 资助金额:
$ 48.27万 - 项目类别:
Biomimetic nanoparticles to enhance the breadth of influenza vaccines
仿生纳米颗粒可增强流感疫苗的广度
- 批准号:
10455053 - 财政年份:2020
- 资助金额:
$ 48.27万 - 项目类别:
Sample-free onsite detection of cocaine using microneedles via laser-treated skin
使用微针通过激光处理的皮肤对可卡因进行无样品现场检测
- 批准号:
9044652 - 财政年份:2016
- 资助金额:
$ 48.27万 - 项目类别:
Laser-facilitated powder-allergen delivery for epicutaneous immunotherapy
用于表皮免疫治疗的激光促进粉末过敏原递送
- 批准号:
8892996 - 财政年份:2014
- 资助金额:
$ 48.27万 - 项目类别:
Laser-facilitated powder-allergen delivery for epicutaneous immunotherapy
用于表皮免疫治疗的激光促进粉末过敏原递送
- 批准号:
8770696 - 财政年份:2014
- 资助金额:
$ 48.27万 - 项目类别:
Laser-facilitated delivery of malarial sporozoites from the skin to liver
激光促进疟疾子孢子从皮肤输送至肝脏
- 批准号:
8495256 - 财政年份:2012
- 资助金额:
$ 48.27万 - 项目类别:
Laser-facilitated delivery of malarial sporozoites from the skin to liver
激光促进疟疾子孢子从皮肤输送至肝脏
- 批准号:
8385605 - 财政年份:2012
- 资助金额:
$ 48.27万 - 项目类别:
Boosting Flu Vaccination without Adjuvant Injection
无需注射佐剂即可加强流感疫苗接种
- 批准号:
8263742 - 财政年份:2011
- 资助金额:
$ 48.27万 - 项目类别:
IEX-1 as a potential biomarker for early detection of myelodysplastic syndromes
IEX-1 作为早期检测骨髓增生异常综合征的潜在生物标志物
- 批准号:
8311631 - 财政年份:2011
- 资助金额:
$ 48.27万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 48.27万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 48.27万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 48.27万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 48.27万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 48.27万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 48.27万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 48.27万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 48.27万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 48.27万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 48.27万 - 项目类别: